Although anticancer systemic
therapy agents clearly lead to improved survival in patients with
cancer, these can come at the cost of serious complications including
cardiotoxicity. Two types of targeted systemic
therapies currently in use for
colorectal cancer (CRC) and
renal cell cancer (RCC), respectively, include the
vascular endothelial growth factor inhibitor
bevacizumab (BVZ) and the
tyrosine kinase inhibitor sunitinib (SNT). Despite the beneficial effects of BVZ and SNT in improving clinical outcomes in the settings of CRC and RCC, there is an increased risk of cardiac dysfunction. The aim of the present study was to determine whether prophylactic administration of renin-angiotensin system (RAS) inhibitors would attenuate the cardiotoxic side effects of BVZ or SNT in a chronic in vivo murine model. A total of 194 wild-type C57Bl/6 male mice received: 1)
0.9% saline, 2) BVZ (10 mg·kg-1·wk-1), or 3) SNT (40 mg·kg-1·day-1) for 4 wk. Within each arm, mice received daily prophylactic treatment with
hydralazine (0.05 mg/ml),
aliskiren (50 mg/kg),
perindopril (4 mg/kg), or
valsartan (2 mg/kg). Although
hydralazine effectively lowered blood pressure in BVZ- or SNT-treated mice, it did not prevent
left ventricular systolic dysfunction. Prophylactic administration of
aliskiren,
perindopril, or
valsartan prevented adverse cardiovascular remodeling in mice treated with either BVZ or SNT. The addition of RAS antagonists also downregulated expression of phosphorylated p38 and Bcl-2-like 19-kDa interacting
protein 3 in SNT-treated mice. In our chronic in vivo murine model, RAS antagonists partially attenuated the development of BVZ- or SNT-mediated cardiac dysfunction. Future clinical studies are warranted to investigate the cardioprotective effects of prophylactic treatment with RAS inhibitors in the settings of CRC and RCC. NEW & NOTEWORTHY In the evolving field of cardio-oncology,
bevacizumab and
sunitinib improve clinical outcomes in the settings of metastatic
colorectal cancer and
renal cell cancer, respectively. These anticancer drugs, however, are associated with an increased risk of
cardiotoxicity. The prophylactic administration of renin-angiotensin system antagonists is partially cardioprotective against
bevacizumab- and
sunitinib-mediated cardiac dysfunction.